Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

Affiliations

• ¹ Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
• ² Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL, USA.
• ³ Mayo Clinic, Rochester, MN, USA.
• ⁴ Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
• ⁵ Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• ⁶ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
• ⁷ Florida Cancer Specialists-South/Sarah Cannon Research Institute, Fort Myers, FL, USA.
• ⁸ GSK, Waltham, MA, USA.
• ⁹ EQRx, Cambridge, MA, USA.
• ¹⁰ Translational Discovery & Development, Boston Pharmaceuticals, Boston, MA, USA.
• ¹¹ Alkermes Incorporated, Waltham, MA, USA.
• ¹² Bicycle Therapeutics, Boston, MA, USA.
• ¹³ Ludwig Center at Harvard, Boston, MA, USA.
• ¹⁴ Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. SISAKOFF@mgh.harvard.edu.